Qiagen NV (NASDAQ:QGEN)‘s stock had its “buy” rating reiterated by Commerzbank AG in a note issued to investors on Thursday. Other …
Qiagen NV
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) (the "Company") today announced details for completion of a synthetic share repurchase plan that combines a direct capital repayment with a reverse stock
Qiagen
Judging by their stock performances over the past six months, Qiagen (NASDAQ:QGEN) has a lot of momentum -- and Opko Health (NASDAQ:OPK) doesn't. But which stock is the better long-term pick for investors? Here's …
Opko Health
The technical rating goes from one, the weakest upside technical, to five, the highest upside technical and focuses on the real-time stock price relative to various moving averages as well as moving averages relative to …
NASDAQ
58.28% of the stock is owned by hedge funds and other institutional investors. Qiagen N.V. (NASDAQ:QGEN) remained flat at $28.35 during …
Shares Sold
Qiagen N.V. (NASDAQ:QGEN)’s stock has been of interest for both individual investors and Wall Street analysts recently. Let’s look at the crowd and equity research sentiment so that we can get a solid idea as to where …
NASDAQ
Even if QGEN can grow NOPAT at a more reasonable, yet still optimistic, 6% compounded annually for the next decade, the stock is worth $17/share today - a 26% downside. Each of these scenarios assumes Qiagen is …
stocks
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) (the "Company") today announced details for …
share repurchase
Global assay technologies major, QIAGEN N.V. (QGEN - Free Report) recently announced the acquisition ... QIAGEN has been trading above the Zacks categorized Medical-Biomed/Genetics industry. The stock has …
QIAGEN
Qiagen N.V. (QGEN) traded on unusually high volume on Jan. 11, as the stock lost 0.7% to close at $28.43. On the day, Qiagen N.V. saw 1.32 million shares trade hands on 12,706 trades. Considering that the stock
Volume Spike